Expertise

Prostate cancer

Primære forskningsområder

Mainly company-sponsored research

Aktuel forskning

Ongoing:  

RECHARGE: A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC)

Role: principal investigator

FASE II: A phase 2, open-label, single-arm, efficacy, and safety study of an investigational (Enzalutamide) drug in patients with hormone-naïve prostate cancer - now open-label

Role: Principal Investigator

PRIMORDIUM (2021-): A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients

Role: Principal Investigator

uTRACE (2025-): An open-label, two-part, phase 2 clinical trial to investigate the safety and diagnostic performance of uPAR PET imaging for non-invasive classification of ISUP grades among patients with localised, untreated prostate cancer.

Role: Principal Investigator

Completed:

BraVac: A Phase 2, Double-Blind, Placebo-Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer

Role: Sub-Investigator

PROSPER: A multinational, phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of an investigational drug in patients with non-metastatic castration-resistant prostate cancer.

Role: Sub- Investigator and Principal Investigator

ARCHES: A multinational, phase 3, randomized, double-blinded, placebo-controlled efficacy and safety study of an investigational drug plus Androgen Deprivation Therapy versus placebo + Androgen Deprivation Therapy in patients with metastatic hormone-sensitive prostate cancer

Role: Sub-Investigator

TERRAIN: A randomized, double-blind, phase 2, efficacy and safety study of an investigational drug versus Bicalutamide in castrate men with metastatic prostate cancer – open-label after.

Role: Sub-Investigator

CORAL: A randomized, multi-site, double-blinded, double-dummy, active control, parallel-group, multidose, efficacy, safety, and tolerability phase 3 study of an oral investigational drug versus Morphine in subjects with chronic moderate to severe pain related to cancer

Role: Sub-Investigator

OREXO: A phase 2, randomized, double-blind, placebo-controlled, dose-finding trial using a sublingual investigational drug to alleviate pain associated with a prostate biopsy procedure

Role: Sub-Investigator

GALAHAD: A phase 2 efficacy and safety study of an investigational drug in men with metastatic castration-resistant prostate cancer with DNA-repair anomalies.

Role: Principal Investigator

PREVAIL: A multinational, double-blind, randomized, placebo-controlled phase 3 trial of an investigational drug + GnRH therapy in chemotherapy-naïve patients with progressive metastatic CRPC who have failed ADT - now open-label

Role: Sub-Investigator

PROSPECT/PROSTVAC: A randomized, double-blind, phase 3 efficacy trial of an investigational vaccine in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer

Role: Sub-Investigator

FERRING:  A prospective observational safety study in patients with advanced prostate cancer treated with a GnRH antagonist or a GnRH agonist

Role: Sub-Investigator

HERO: A multinational phase 3, randomized, open-label, parallel Group study to evaluate the safety and efficacy of an investigational drug in men with advanced prostate cancer

Role: Principal Investigator

PREMISE: A European prospective observational study assessing the efficacy and outcomes associated with AR-targeted treatment in patients with metastatic castration-resistant prostate cancer.

Role: Sub-Investigator

DAROL: Darolutamide Observational Study in nonmetastatic castration-resistant prostate cancer patients

Role: Principal Investigator

Mulige interessekonflikter

Advisory board member for the “Danish Medicines Council” regarding Prostate cancer (2020 - )